Amgen Inc. $AMGN Shares Sold by KFG Wealth Management LLC

KFG Wealth Management LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 37.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,248 shares of the medical research company’s stock after selling 3,693 shares during the quarter. KFG Wealth Management LLC’s holdings in Amgen were worth $2,045,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Amgen by 0.3% during the third quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock worth $15,204,047,000 after purchasing an additional 165,281 shares in the last quarter. State Street Corp increased its position in Amgen by 0.6% during the 2nd quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock worth $8,196,775,000 after purchasing an additional 177,035 shares during the period. Capital International Investors raised its stake in shares of Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after buying an additional 282,219 shares in the last quarter. Capital World Investors raised its stake in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after buying an additional 1,935,876 shares in the last quarter. Finally, Capital Research Global Investors lifted its holdings in shares of Amgen by 2.7% in the 3rd quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock valued at $1,335,168,000 after buying an additional 122,631 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Argus upped their price objective on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Rothschild & Co Redburn boosted their target price on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Guggenheim upped their price target on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Cantor Fitzgerald increased their price target on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Finally, HSBC reissued a “buy” rating and set a $425.00 price target on shares of Amgen in a research note on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $354.60.

Amgen Stock Performance

Shares of AMGN opened at $342.57 on Tuesday. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The stock has a market cap of $184.67 billion, a P/E ratio of 24.07, a PEG ratio of 3.45 and a beta of 0.47. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The company has a 50-day moving average of $363.51 and a two-hundred day moving average of $333.65.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period last year, the company posted $5.31 EPS. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.